Beijing Aerospace Changfeng Co.Ltd(600855) announced that on December 31, 2021, the company and China Changfeng electromechanical technology research and Design Institute (the external name of China Aerospace Science and industry Defense Technology Research Institute, hereinafter referred to as "Electromechanical institute") signed a joint development contract on "research and development of extracorporeal life support cardiopulmonary bypass equipment" in Beijing, and the two sides jointly developed "extracorporeal life support cardiopulmonary bypass equipment".
According to the joint development contract, after the R & D content is completed, the equipment will be owned by Beijing Aerospace Changfeng Co.Ltd(600855) and one set of ECMO host will be completed for the verification of core key technologies; In addition to equipment, the ownership of intellectual property rights, technical data and other achievements shall be divided according to the proportion of mechanical and Electrical Institute accounting for 70% and Beijing Aerospace Changfeng Co.Ltd(600855) accounting for 30%; For the technical achievements that have not been completed or passed the patent application, both parties shall jointly manage them as trade secrets, with the ownership of Electromechanical institute accounting for 70% and Beijing Aerospace Changfeng Co.Ltd(600855) accounting for 30%. After the completion of research and development, Beijing Aerospace Changfeng Co.Ltd(600855) carry out the industrialization of the whole product of cardiopulmonary bypass system for extracorporeal life support, and the Electromechanical institute will charge patent royalties or technical achievement royalties.
According to the company, extracorporeal life support cardiopulmonary bypass equipment (also known as ECMO, extracorporeal membrane oxygenation) plays a key role in the treatment of patients with cardiopulmonary failure, especially in the treatment of severe patients with "covid-19" pneumonia. With the aggravation of aging, the number of critical cases relying on ECMO is increasing rapidly. At present, China has no domestic products, and equipment and consumables are heavily dependent on imports. The incidence of bleeding / thrombosis and other complications in the clinical use of existing imported products is high, and there are many problems, such as complex devices, inconvenient use, difficult operation and management, limited clinical indications and application scenarios, etc. Therefore, the independent research and development of high-performance ECMO system by Electromechanical institute not only has strategic significance, but also has broad market prospects.
(Shanghai Securities News · China Securities Network)
